AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Backup compound to AstraZeneca’s failed Exanta is being investigated for a stability limitation; Crestor is the only branded statin to increase U.S. market share during 2008.
You may also be interested in...
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards